IPAMORELIN

IPAMORELIN is a synthetic pentapeptide belonging to the growth hormone-releasing peptide (GHRP) class, acting as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a). AminoOptimization Group supplies it as a lyophilised research powder in 5 mg and 10 mg presentations, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.

What is IPAMORELIN?

IPAMORELIN is a five-amino-acid peptide built on the sequence Aib-His-D-2-Nal-D-Phe-Lys, with C-terminal amidation. The Aib (α-aminoisobutyric acid) residue and the D-configured naphthylalanine and phenylalanine substitutions are non-proteinogenic — this exact arrangement does not occur in natural peptides — and published structure-activity work attributes to them a marked resistance to enzymatic cleavage relative to earlier compounds in the same pharmacological class.

It belongs to the same family as growth hormone-releasing peptide-6 (GHRP-6) and growth hormone-releasing peptide-2 (GHRP-2), all of which act on the ghrelin receptor rather than the growth hormone-releasing hormone receptor targeted by GHRH analogues such as CJC-1295. What comparative receptor-binding studies describe as distinguishing IPAMORELIN within this family is selectivity: at comparable receptor occupancy it is reported to produce substantially less activation of secondary pathways — corticotropin and prolactin release in particular — than hexarelin or GHRP-6 produce. This selectivity profile is the reason the compound recurs in receptor-pharmacology study designs as a comparatively narrow GHS-R1a probe.

Because it signals through a distinct receptor from GHRH analogues, IPAMORELIN is frequently examined in combination protocols alongside compounds such as CJC-1295 (No DAC), where the two-receptor approach is used to investigate interaction between ghrelin-receptor and GHRH-receptor signalling in model systems.

Specifications

• Compound: IPAMORELIN
• CAS number: 170851-70-4
• Molecular formula: C₃₈H₄₉N₉O₅
• Molecular weight: 711.85 g/mol
• Purity: 99% by HPLC
• Presentation: Lyophilised powder, sealed vial
• Available sizes: 5 mg, 10 mg
• Physical form: White to off-white powder
• Classification: Research peptide — not for human or veterinary use

Research context

Published research on IPAMORELIN centres on its use as a selective tool for probing GHS-R1a signalling independently of the secondary endocrine pathways that less selective secretagogues also activate. Study designs exploit this selectivity to isolate growth hormone secretagogue signalling from the corticotropic and lactotropic effects that complicate interpretation when less selective ligands are used.

It is also examined in combination protocols alongside GHRH-receptor agonists, where researchers use the two-receptor approach to investigate whether concurrent signalling through GHS-R1a and the GHRH receptor produces additive or synergistic effects on pulsatile secretion in model systems.

None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.

Reconstitution

Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most often specified for multi-use laboratory preparations; sterile water is typical where a single-use protocol is required.

Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and let the material dissolve without agitation. Peptides are susceptible to shear stress, so do not shake the vial — swirl gently if needed. Full dissolution is typically achieved within a few minutes at room temperature.

Working concentration depends on how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.

Storage and stability

Before reconstitution: store the sealed vial at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state, and brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.

After reconstitution: refrigerate at 2–8 °C and protect from light. Peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.

Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.

Certificate of Analysis

Every lot is tested by high-performance liquid chromatography, and the purity figure above refers to analytical results for the specific lot supplied, not to a generic specification. A Certificate of Analysis is available on request, and lot-specific documentation can be provided before purchase if your protocol requires it.

Purity by HPLC describes the proportion of target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.

Handling and safety

Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.

Frequently asked questions

What distinguishes IPAMORELIN from GHRP-6 and GHRP-2?

All three are growth hormone secretagogue receptor agonists, but comparative receptor-binding studies describe IPAMORELIN as substantially more selective, producing far less activation of corticotropin and prolactin release than GHRP-6 or GHRP-2 at comparable receptor occupancy. This selectivity is the property most often cited in the literature for its use as a pathway-specific probe.

Is IPAMORELIN approved in Canada?

No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.

How much diluent should be used?

That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.

How long is reconstituted material usable?

Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.

Do you provide a Certificate of Analysis?

Yes — lot-specific, available on request, including before purchase.

Research use only

This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.